CPEB3 suppresses gastric cancer progression by inhibiting ADAR1-mediated RNA editing via localizing ADAR1 mRNA to P...

Area of Science:

• Molecular Biology
• Oncology
• Gene Therapy

Background:

• Gastric cancer (GC) progression involves complex interactions between RNA-binding proteins and RNAs.
• Understanding these interactions is crucial for developing effective GC therapies.

Purpose of the Study:

• To investigate the role of cytoplasmic polyadenylation element-binding protein 3 (CPEB3) in gastric cancer progression.
• To elucidate the underlying molecular mechanisms by which CPEB3 affects GC.

Main Methods:

• Bioinformatic analysis to identify potential GC-related RNA-binding proteins.
• In vitro and in vivo experiments to assess CPEB3's function in GC cells and tumor models.
• Biochemical assays (e.g., microscale thermophoresis) to confirm protein-RNA interactions.
• Development and testing of Adeno-Associated Virus serotype 9 (AAV9)-CPEB3 for gene therapy.

Main Results:

• CPEB3 was found to be downregulated in GC and correlated with poor prognosis.
• CPEB3 suppressed GC cell proliferation, invasion, migration, tumor growth, and metastasis.
• CPEB3 directly interacted with ADAR1 mRNA, inhibiting its translation and subsequent RNA editing by sequestering it in P bodies.
• AAV9-CPEB3 administration inhibited GC growth and metastasis in mouse models, with observed liver toxicity but no kidney damage.

Conclusions:

• CPEB3 acts as a tumor suppressor in gastric cancer by inhibiting ADAR1-mediated RNA editing.
• The mechanism involves CPEB3-mediated localization of ADAR1 mRNA to processing bodies (P bodies).
• AAV9-CPEB3 demonstrates therapeutic potential for GC, warranting further investigation into its safety profile.